Nektar presents durability data and H.C. Wainwright keeps Buy for Nektar Therapeutics stock

Published on 10/07/2026 at 08:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright kept a USD 185.00 target on October 2, 2026. Nektar Therapeutics stock costs EUR 35.48 on October 7, 2026 after EUR 35.49.

NKTR, US6402683063, Illustration mit AI erstellt.

Nektar Therapeutics (US6402683063) was trading at EUR 35.48 at Lang & Schwarz on October 7, 2026 at 8:07 a.m. CEST, down 0.03 percent versus the EUR 35.49 prior close. On October 1, 2026, Nektar presented long-term rezpegaldesleukin data at the European Academy of Dermatology and Venereology Congress, while H.C. Wainwright reiterated a Buy rating and a USD 185.00 price target, according to Investing.com on October 2, 2026.

Rezpegaldesleukin data deepen the story

The company highlighted durability in the Phase 2b REZOLVE-AA study for severe-to-very-severe alopecia areata. Among eight patients who reached a SALT score of 20 or lower after 52 weeks of treatment, 75.00 percent maintained that response after four months off treatment and 63.00 percent after six months.

BioSpace reported on the October 1, 2026 release that the share of patients reaching a SALT score of 10 or lower rose from 7.00 percent at Week 52 to 19.00 percent after six months off treatment. Nektar also said its Phase 3 ZENITH AA study is planned to begin in early 2027, with 850 patients and a primary endpoint based on a SALT score of 20 or lower at Week 52.

Clinical progress meets financial pressure

The latest reported quarter adds a counterweight to the clinical narrative. For the second quarter of 2026, Nektar generated USD 10.13 million in revenue and posted a USD 40.30 million net loss, according to MarketBeat. Diluted earnings per share were negative USD 1.23, compared with the consensus estimate of negative USD 1.97, a USD 0.74 improvement versus expectations, while revenue came in below the USD 10.43 million consensus figure.

The financial comparison matters because Nektar remains a clinical-stage biotechnology company whose valuation depends heavily on development milestones rather than product sales. The second-quarter loss and revenue shortfall therefore sit alongside the durability data as opposing signals for the stock.

Stock remains below its yearly high

On Nasdaq, Nektar last traded at USD 39.91 on October 6, 2026 at 4:00 p.m. EDT. The current 52-week range is USD 33.40 to USD 109.00, while the market capitalization is USD 1.1 billion as of October 6, 2026.

Price source: Lang & Schwarz. The further course of trading is shown by the continuously updated real-time quote of Nektar Therapeutics stock.